Sutimlimab,
does it really help with 26-week hemoglobin and transfusion-free composite response in cold agglutinin disease?
research showsGrade C, 54 points. CADENZA found composite response in 16/22 (73%) with sutimlimab versus 3/20 (15%) with placebo, an absolute difference of 58 points and OR 15.9 (95% CI 2.9 to 88.0). It remains a surrogate composite from one 42-patient Sanofi-funded trial.
ads claimHemoglobin improvement and transfusion avoidance should not be expanded into proven long-term survival or hospitalization benefit.
Useful facts when choosing a product
- Enjaymo was authorized in South Korea for cold agglutinin disease in 2023.
- It is an intravenous antibody inhibiting complement C1s.
What the research actually shows
Four-gate review: ① Total under 200 ② listed item ③ 42 randomized ④ unavoidable in this rare disease, so not counted. ① No placebo group ② not a listed item ③ CADENZA had 20 placebo patients ④ not applicable. Axis 6 B0 evidence ① Allocation concealment: "Patients were randomly assigned 1:1 to sutimlimab or placebo via an interactive response technology system." ② Masking: "randomized, double-blind, placebo-controlled" ③ Analysis population and missingness: "The mITT population included all randomized patients who received any amount of study drug"; discontinuation before week 23 yielded unknown response status. ④ Prespecified primary endpoint: "The primary efficacy endpoint was a composite response" - consistent with NCT03347422
Why this is classified as C (54)
A large placebo-controlled composite response is capped by the surrogate endpoint and single manufacturer-funded trial, giving C with 54 points.
Counterpoint. The small sample was unavoidable in a rare disease and was not counted as a defect, although precision remains limited.
Rejudgment record. Source checked — CADENZA placebo-controlled composite response with surrogate and single-manufacturer-trial limits
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| 26-week composite response | C | The result was 73% versus 15%. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| CADENZA | Multicenter randomized double-blind placebo-controlled phase 3 trial | 20 | Sanofi | 26-week composite of hemoglobin increase and avoidance of transfusion and prohibited therapy | 16/22 (73%) vs 3/20 (15%), absolute difference 58 points, OR 15.9 (95% CI 2.9 to 88.0) | Pivotal manufacturer-funded placebo-controlled trial |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] Benefit of Sutimlimab for 26-Week Hemoglobin and Transfusion-Free Composite Response in Cold Agglutinin Disease, a Surrogate Outcome — Evidence Grade C·54. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/general/sutimlimab-cold-agglutinin-disease-composite-response/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.